Linked Life Data

16828624

Source:http://linkedlifedata.com/resource/pubmed/id/16828624

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2006-7-10
pubmed:abstractText
Cardiac syndrome X (CSX), or angina with no flow-limiting stenosis on coronary angiogram, has been regarded as a condition with an excellent prognosis despite variable symptomatic improvement. Newer data show that patients with CSX with endothelial dysfunction have an increased risk for future adverse cardiac events. Current hypotheses of CSX pathophysiology emphasize a dysfunctional vascular endothelium that leads to microvascular ischemia. Treatments that target improving endothelial function, such as statins, angiotensin-converting enzyme inhibitors, estrogen, and lifestyle modification, are promising additions to treatment regimens for CSX. The goal of this article is to provide information for improved diagnosis, risk stratification, and therapy for the population with CSX.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1555-7162
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
119
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
560-6
pubmed:dateRevised
2007-10-30
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Cardiac syndrome X and endothelial dysfunction: new concepts in prognosis and treatment.
pubmed:affiliation
Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, Arizona 85259, USA.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't